IFNg, produced by NK cells and other cell types, plays a critical role in killing pathogen-infected cells and in defending against tumor cells. However, overproduction of IFNg is also dangerous to the body and can cause autoimmune diseases. But exactly how the body tightly controls IFNg production and, therefore, NK-cell activity is not known.

The study, published in the May issue of the journal Immunity, looked at substances called pro-inflammatory cytokines, which cause NK cells to make IFNg and stimulate their activity. It also looked at transforming growth factor beta (TGFb), a substance also made by NK cells that lowers IFNg production.

The research, by investigators with the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, found that the pro-inflammatory cytokines not only cause NK cells to make IFNg, but they also shut down TGFb signaling, which inhibits production of IFNg.

That is, the cytokines not only increase some positive regulators of IFNg production, but they also shut down the TGFb signals that inhibit IFNg production.

In addition, the scientists found that TGFb turns down IFNg production and, therefore, NK cell activity both directly and indirectly.

The direct mechanism turns off the IFNg gene itself. The indirectly mechanism blocks a protein that normally turns up IFNg production.

"Our findings provide important details about the fine balance between positive and negative regulators of IFNg production in NK cells," says principal investigator Michael A. Caligiuri, director of the OSU Comprehensive Cancer Center. "Mother Nature uses a symphony of cytokines that result in exquisi
'"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University
23-May-2006